soul trial oral semaglutide cardiovascular outcomes 2024 results nejm Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results Oral Semaglutide Reduces CV Events

GLP1 Medication Bottom Line GLP-1 receptor agonists are not a trend or a celebrity weight loss shortcut

This typically includes periodic assessment of HbA1c, renal function, and cardiovascular risk factors

The findings from this Delphi study aim to help guide treatment decisions in adults with CKD and T2D with or without overweight/obesity, and can be adapted to suit local health system contexts to ultimately improve timely treatment and long-term outcomes for this population

12.112 hastalk analizde akcier, meme, kolorektal kanser ve hepatoseller karsinomda evre IVe ilerleme oran, DPP-4 inhibitr kullananlara kyasla GLP-1 grubunda belirgin ekilde daha dk bulundu

The 68-week treatment period was followed by a 7-week follow-up period during which patients did not receive Wegovy or placebo

Hypertension (2020) 75(4):9911001